Advaxis Inc.
Description Advaxis, Inc., a clinical development stage biotechnology company, engages in the development of immunotherapies for cancer and infectious diseases. The companys platform technology generates an immune response by serving as its own adjuvant, directing antigen presentation, increasing tumor infiltrating killer T-cells, and decreasing Tregs/MDSCs in the tumor. It has approximately 15 distinct constructs in various stages of development, directly developed by the company and through strategic collaborations. The companys products in clinical development stage include ADXS-HPV that is being evaluated in clinical trials for cervical cancer, CIN 2/3, head and neck cancer, and anal cancer. Its products in clinical development stage also comprise ADXS-PSA for prostate cancer; and ADXS-cHER2 for overexpressing cancers, such as breast, gastric, and other cancers in humans, as well as for osteosarcoma in canines. The company was founded in 2002 and is based in Princeton, New Jersey. To view the detailed information, you need to SUBSCRIBE with us. |
 |